Fundamental Analysis of MILESTONE PHARMACEUTICALS IN(NASDAQ:MIST) stock

Fundamental Rating

MIST gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. While MIST seems to be doing ok healthwise, there are quite some concerns on its profitability. MIST does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year MIST has reported negative net income.

In the past year MIST has reported a negative cash flow from operations.

In the past 5 years MIST always reported negative net income.

In the past 5 years MIST always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -79.34%, MIST is not doing good in the industry: 72.82% of the companies in the same industry are doing better.

The Return On Equity of MIST (-355.86%) is worse than 80.00% of its industry peers.

		Industry Rank	Sector Rank
ROA	-79.34%
ROE	-355.86%
ROIC	N/A

ROA(3y)-64.49%

ROA(5y)-54.31%

ROE(3y)-160.67%

ROE(5y)-113%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MIST so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

MIST does not have a ROIC to compare to the WACC, probably because it is not profitable.

MIST has less shares outstanding than it did 1 year ago.

Compared to 5 years ago, MIST has more shares outstanding

MIST has a worse debt/assets ratio than last year.

2.2 Solvency

MIST has an Altman-Z score of -5.92. This is a bad value and indicates that MIST is not financially healthy and even has some risk of bankruptcy.

MIST has a worse Altman-Z score (-5.92) than 65.64% of its industry peers.

MIST has a Debt/Equity ratio of 2.97. This is a high value indicating a heavy dependency on external financing.

MIST has a worse Debt to Equity ratio (2.97) than 84.10% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	2.97
Debt/FCF	N/A
Altman-Z	-5.92

ROIC/WACCN/A

WACC7.12%

2.3 Liquidity

MIST has a Current Ratio of 10.11. This indicates that MIST is financially healthy and has no problem in meeting its short term obligations.

With an excellent Current ratio value of 10.11, MIST belongs to the best of the industry, outperforming 86.15% of the companies in the same industry.

A Quick Ratio of 10.11 indicates that MIST has no problem at all paying its short term obligations.

MIST has a better Quick ratio (10.11) than 86.15% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	10.11
Quick Ratio	10.11

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

MIST shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.46%.

MIST shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -80.00%.

EPS 1Y (TTM)-1.46%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-3.23%

Revenue 1Y (TTM)-80%

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2Q-100%

3.2 Future

MIST is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 43.02% yearly.

MIST is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 219.57% yearly.

EPS Next Y15.61%

EPS Next 2Y-6.48%

EPS Next 3Y17.41%

EPS Next 5Y43.02%

Revenue Next Year-100%

Revenue Next 2Y267.42%

Revenue Next 3Y344.04%

Revenue Next 5Y219.57%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

MIST reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year MIST is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as MIST's earnings are expected to grow with 17.41% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-6.48%

EPS Next 3Y17.41%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

MIST does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

MILESTONE PHARMACEUTICALS IN

NASDAQ:MIST (4/26/2024, 7:03:48 PM)

After market: 1.58 +0.04 (+2.6%)

1.54

-0.04 (-2.53%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap81.85M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-79.34%
ROE	-355.86%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.01

Health

		Industry Rank	Sector Rank
Debt/Equity	2.97
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	10.11
Quick Ratio	10.11
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-1.46%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y15.61%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-80%

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

MILESTONE PHARMACEUTICALS IN (MIST)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens